Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Shapiro

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 27, 2003
Surveillance of infectious complications associated with central venous access devices in children with haemophiliaM D Tarantino, A Lail, S M Donfield, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2011
Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)G Young, A D Shapiro, C E Walsh, et al.
Thrombosis and Haemostasis|January 1, 1996
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia BA D Shapiro, M V Ragni, J M Lusher, et al.
The Journal of Pediatrics|October 1, 1986
Vitamin K deficiency in the newborn infant: prevalence and perinatal risk factorsA D Shapiro, L J Jacobson, M E Armon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2016
A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand diseaseS L Sood, A H James, M V Ragni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 13, 2016
Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG StudiesD V Quon, R Klamroth, R Kulkarni, et al.
Journal of Thrombosis and Haemostasis : JTH|May 28, 2008
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsV S Blanchette, A D Shapiro, R J Liesner, et al.
The Journal of Clinical Investigation|April 1, 1991
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domainK A Cooney, W C Nichols, M E Bruck, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009
Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia AL A Valentino, M Recht, J Dipaola, et al.
Pediatrics|December 4, 2001
Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia StudyA D Shapiro, S M Donfield, H S Lynn, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 27, 2003
Surveillance of infectious complications associated with central venous access devices in children with haemophiliaM D Tarantino, A Lail, S M Donfield, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2011
Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)G Young, A D Shapiro, C E Walsh, et al.
Thrombosis and Haemostasis|January 1, 1996
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia BA D Shapiro, M V Ragni, J M Lusher, et al.
The Journal of Pediatrics|October 1, 1986
Vitamin K deficiency in the newborn infant: prevalence and perinatal risk factorsA D Shapiro, L J Jacobson, M E Armon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2016
A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand diseaseS L Sood, A H James, M V Ragni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 13, 2016
Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG StudiesD V Quon, R Klamroth, R Kulkarni, et al.
Journal of Thrombosis and Haemostasis : JTH|May 28, 2008
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsV S Blanchette, A D Shapiro, R J Liesner, et al.
The Journal of Clinical Investigation|April 1, 1991
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domainK A Cooney, W C Nichols, M E Bruck, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 21, 2009
Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia AL A Valentino, M Recht, J Dipaola, et al.
Pediatrics|December 4, 2001
Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia StudyA D Shapiro, S M Donfield, H S Lynn, et al.
Pageof 8